murcia

Portal de Totana

www.portaldetotana.com

Totana - SpanishTotana - English
detail of Totana

 

AELIP D'Genes and participate in Edinburgh at the European Conference on Rare Diseases (28/05/2016)

The Association of Rare Diseases D'Genes and the Association of Relatives and Affected Lipodystrophies (AELIP) participate in the day of Rare Diseases International, together with the Spanish Federation for Rare Diseases (FEDER) and the Latin American Alliance ER (Aliber) , held these days in Edinburgh.

After seven successful editions, this year 2016 is celebrated the 8th edition of the European Conference on Rare Diseases and Orphan Drugs (ECRD), whose centerpiece tour this year about changing factors in rare diseases.

This biennial conference is a unique opportunity to meet and exchange experiences and is configured as a great opportunity to share and make contact with other members of the group of rare diseases.

ECRD brings together more than 80 speakers and over 800 participants, addressing six themes in two days: from the latest data from research to development of new treatments, innovation in healthcare, social care and support at European, national and regional level .

For the first time new formats are shown in Edinburgh to enrich the educational experience and has scheduled a session to put patients, researchers and industry, interactive roundtables, surveys of the public, lunches and coffee breaks contact for networking and sessions posters.

Thus, in this meeting, which is being held in Edinburgh from May 26 and runs until Saturday morning factors change research are addressed;

in diagnosis;

development, authorization and access to medicines;

in providing assistance;

in social policy or global society, among others.

Source: D´Genes

Notice
UNE-EN ISO 9001:2000 - ER-0131/2006 © 2018 Alamo Networks S.L. - C/Alamo 8, 30850 Totana (Murcia) Privacy policy - Legal notice Región de Murcia
Este sitio web utiliza cookies para facilitar y mejorar la navegación. Si continúas navegando, consideramos que aceptas su uso. Más información